Marinomed Biotech AG (WBO:MARI) Beta: -0.0345 (As of Jun. 26, 2026)


WBO:MARI Marinomed Biotech AG WBO:MARI
42 GF Score
Price €9.25
GF Value €18.48
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Beta?

Marinomed Biotech AG WBO:MARI +2.78% 42 Beta is -0.0345 as of Jun. 26, 2026. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.48 (Possible Value Trap). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Marinomed Biotech AG's Beta is -0.0345.


Marinomed Biotech AG  (WBO:MARI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Marinomed Biotech AG Beta Related Terms


Marinomed Biotech AG Beta Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Beta Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.21 0.16 -0.04 -0.17

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.06 -0.04 0.07 -0.17

WBO:MARI vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Marinomed Biotech AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinomed Biotech AG Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Beta distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's Beta falls into.


WBO:MARI
42GF Score
Marinomed Biotech AG WBO:MARI
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0345 mean?
Marinomed Biotech AG (WBO:MARI) has a Beta of -0.0345 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Marinomed Biotech AG and its competitors.
Is Marinomed Biotech AG's Beta too high?
Marinomed Biotech AG's current Beta is -0.0345. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Beta compare to VRTX and REGN?
Marinomed Biotech AG's Beta of -0.0345 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Beta is -0.0345. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.48, compared to a current price of €9.25 — trading 49.9% below its estimated fair value. The current Beta is -0.0345. Marinomed Biotech AG's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Beta is -0.0345 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €9.25 is trading 49.9% below its estimated GF Value™ of €18.48. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Beta: -0.0345
  • GF Value™: €18.48 vs. price of €9.25 (49.9% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score

Get the complete analysis for WBO:MARI

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.25
Price
€18.48
GF Value